glp-1 weight loss oral FDA Approves Semaglutide: First Pill The Food and Drug Administration
Description
elegans life span assay
Smits, M
In the ATTAIN-1 trial, the highest dose produced an average ~12.4% weight loss (~27 lbs) for those who stayed on treatment
The results showed high heterogeneity of weight loss from the baseline weight between individuals even at the highest dose of tirzepatide 38.4 to 9.0 kg and mean 22.1 kg
The introduction of GLP-1 receptor agonists, such as semaglutide, may further complicate the clinical picture in this high-risk population
